Hazem Ayesh is an Endocrinology/Metabolic physician affiliated with Deaconess Hospital. OpenAlex indexes 87 publications with 531 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
120 SE 4th St
Evansville, IN 477081607
Telephone
812-426-6638Provider last certified this registry record 16 Jun 2024.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20255 payments
- Novo Nordisk IncProgram year20253 payments
- Averitas Pharma Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
59.7%Insulin Analog21.9%Lantus Solostar48%Insulin Lispro Kwikpen U-10015%Humalog Kwikpen U-10013%Tresiba Flextouch U-10013%Novolog Flexpen12%Part D<11 patientsGLP-1 receptor agonist16%Ozempic76%Mounjaro24%Part D<11 patients+ 3 more classes in this area
Hormonal (systemic)
33.5%l-Thyroxine25.3%Levothyroxine Sodium72%Synthroid28%Part D≥39 patientsThyroid Hormone Synthesis Inhibitor5.2%Methimazole100%Part D≥16 patients+ 1 more class in this area
Cardiovascular
6.7%Statin6.7%Rosuvastatin Calcium58%Atorvastatin Calcium42%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials
Endocrinology Diabetes & Metabolism
2026 - Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials
Journal of Basic and Clinical Physiology and Pharmacology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”